1. Home
  2. NGNE vs VTEX Comparison

NGNE vs VTEX Comparison

Compare NGNE & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.99

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo VTEX

VTEX

VTEX

HOLD

Current Price

$3.86

Market Cap

755.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
VTEX
Founded
2003
1999
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
755.3M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
NGNE
VTEX
Price
$35.99
$3.86
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
$63.57
$5.97
AVG Volume (30 Days)
174.1K
929.6K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$12.78
Revenue Next Year
N/A
$9.63
P/E Ratio
N/A
$43.33
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$2.84
52 Week High
$43.66
$4.73

Technical Indicators

Market Signals
Indicator
NGNE
VTEX
Relative Strength Index (RSI) 53.66 39.79
Support Level $31.83 $3.73
Resistance Level $43.66 $4.20
Average True Range (ATR) 2.07 0.19
MACD 0.05 -0.07
Stochastic Oscillator 72.75 14.86

Price Performance

Historical Comparison
NGNE
VTEX

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

Share on Social Networks: